Studies on antigenicity of the polyethylene glycol (PEG)-modified uricase
- PMID: 2412977
- DOI: 10.1016/0192-0561(85)90158-4
Studies on antigenicity of the polyethylene glycol (PEG)-modified uricase
Abstract
The purified uricase (urate: oxygen oxidoreductase, EC 1.7.3.3) from Candida utilis was modified to varying degrees with monomethoxypolyethylene glycol (PEG) of different molecular weights using cyanuric chloride as the coupling reagent. The PEG-uricase conjugates were examined on their immunological properties by means of ring test and passive cutaneous anaphylaxis (PCA). As increasing amounts of PEG were attached to uricase, it showed decreasing ability to elicit antibody production in rabbits. When sufficient polymers were attached, the modified uricase was devoid of the capacity to combine in vivo and in vitro with antibodies from guinea pigs injected with the unmodified uricase, however, were still able to react with antibodies to PEG-uricase conjugate. Antibodies against PEG-uricase conjugates also reacted with PEG modified superoxide dismutase (superoxide: superoxide oxidoreductase, EC 1.15.1.1). These results indicate that the coupling of PEG to uricase resulted in the loss of original antigenicity and immunogenicity, but in the appearance of new antigenicity and immunogenicity which never showed any cross-reactions against the native uricase.
Similar articles
-
Induction of tolerance in mice by uricase and monomethoxypolyethylene glycol-modified uricase.Int Arch Allergy Appl Immunol. 1984;75(1):58-67. doi: 10.1159/000233591. Int Arch Allergy Appl Immunol. 1984. PMID: 6746105
-
Improved modification of yeast uricase with polyethylene glycol, accompanied with nonimmunoreactivity towards anti-uricase serum and high enzymic activity.Enzyme. 1981;26(1):49-53. doi: 10.1159/000459146. Enzyme. 1981. PMID: 7194181
-
Immunological properties of uricase conjugated to neutral soluble polymers.Bioconjug Chem. 2001 Jul-Aug;12(4):515-22. doi: 10.1021/bc000119x. Bioconjug Chem. 2001. PMID: 11459455
-
Pegloticase, a polyethylene glycol conjugate of uricase for the potential intravenous treatment of gout.Curr Opin Investig Drugs. 2008 Apr;9(4):422-9. Curr Opin Investig Drugs. 2008. PMID: 18393109 Review.
-
PEG-uricase in the management of treatment-resistant gout and hyperuricemia.Adv Drug Deliv Rev. 2008 Jan 3;60(1):59-68. doi: 10.1016/j.addr.2007.06.011. Epub 2007 Aug 14. Adv Drug Deliv Rev. 2008. PMID: 17826865 Review.
Cited by
-
Pegylated interferons: what role will they play in the treatment of chronic hepatitis C?Curr Gastroenterol Rep. 2001 Feb;3(1):30-7. doi: 10.1007/s11894-001-0038-z. Curr Gastroenterol Rep. 2001. PMID: 11177692 Review.
-
Uricases as therapeutic agents to treat refractory gout: Current states and future directions.Drug Dev Res. 2012 Mar 1;73(2):66-72. doi: 10.1002/ddr.20493. Epub 2011 Dec 29. Drug Dev Res. 2012. PMID: 22665944 Free PMC article.
-
Profile of peginesatide and its potential for the treatment of anemia in adults with chronic kidney disease who are on dialysis.J Blood Med. 2012;3:25-31. doi: 10.2147/JBM.S23270. Epub 2012 May 23. J Blood Med. 2012. PMID: 22719216 Free PMC article.
-
Optimizing Pharmacological and Immunological Properties of Therapeutic Proteins Through PEGylation: Investigating Key Parameters and Their Impact.Drug Des Devel Ther. 2024 Nov 7;18:5041-5062. doi: 10.2147/DDDT.S481420. eCollection 2024. Drug Des Devel Ther. 2024. PMID: 39529843 Free PMC article. Review.
-
"Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung.J Virol. 2001 May;75(10):4792-801. doi: 10.1128/JVI.75.10.4792-4801.2001. J Virol. 2001. PMID: 11312351 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials